Floatz logo

Selinexor

Amyloid

Weill Medical College of Cornell UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Amyloid cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
fx-1006a
Pfizer
Phase 4BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →